Research progress of resveratrol on the prevention and treatment of colorectal cancer

doi:10.3760/cma.j.issn.1673-422X.2016.01.019

Abstract

Abstract: Recent studies show that resveratrol is characterized with its antioxidative and antiinflammatory effects, and plays an important role in the prevention and treatment of colorectal cancer through modulating intracellular carbohydrate and ceramide metabolism, activating tumor suppressors such as activator of transcription 3 and peroxisome proliferatorsactivated receptor γ, downregulating the expression of kirsten rat sarcoma viral oncogene and inhibiting the epithelialtomesenchymal transition process of cancer cells. In addition, resveratrol exhibits its broad application prospects in combination therapy.

Key words: Colorectal neoplasms, Resveratrol

Xu Jiahui, Liu Deying, Xu Zhijun, Ma Wenxia, Zhang Qingling. Research progress of resveratrol on the prevention and treatment of colorectal cancer[J]. Journal of International Oncology, 2016, 43(1): 67-70.

References

［1］ Talero E, AvilaRoman J, Motilva V. Chemoprevention with phytonutrients and microalgae products in chronic inflammation and colon cancer［J］. Curr Pharm Des, 2012, 18(26): 3939-3965. ［2］ Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans［J］. Biochim Biophys Acta, 2015, 1852(6): 1071-1113. DOI:10.1016/j.bbadis.2015.01.014. ［3］季佳文, 周怀君. 白藜芦醇对肿瘤中微小RNA的调节作用［J］. 国际肿瘤学杂志, 2013, 40(8): 587-590. DOI:10.3760/cma.j.issn.1673422X.2013.08.009. ［4］倪琴, 周怀君. 白藜芦醇在妇科肿瘤中的研究进展［J］. 国际肿瘤学杂志, 2014, 41(7): 526-529. DOI:10.3760/cma.j.issn.1673422X.2014.07.014 ［5］ Pangeni R, Sahni JK, Ali J, et al. Resveratrol: review on therapeutic potential and recent advances in drug delivery［J］. Expert Opin Drug Deliv, 2014, 11(8): 1285-1298. DOI:10.1517/17425247.2014.919253. ［6］ Howells LM, Berry DP, Elliott PJ, et al. Phase Ⅰ randomized, doubleblind pilot study of micronized resveratrol (srt501) in patients with hepatic metastasessafety, pharmacokinetics, and pharmacodynamics［J］. Cancer Prev Res (Phila), 2011, 4(9): 14191425. DOI:10.1158/1940-6207.CAPR-11-0148. ［7］ Temraz S, Mukherji D, Shamseddine A. Potential targets for colorectal cancer prevention［J］. Int J Mol Sci, 2013, 14(9): 17279-17303. DOI:10.3390/ijms140917279. ［8］ Serra D, Rufino AT, Mendes AF, et al. Resveratrol modulates cytokineinduced Jak/STAT activation more efficiently than 5aminosalicylic acid: an in vitro approach［J］. PLoS One, 2014, 9(10): e109048. DOI:10.1371/journal.pone.0109048. ［9］ Sengottuvelan M, Deeptha K, Nalini N. Resveratrol ameliorates DNA damage, prooxidant and antioxidant imbalance in 1, 2dimethylhydrazine induced rat colon carcinogenesis［J］. Chem Biol Interact, 2009, 181(2): 193-201. DOI:10.1016/j.cbi.2009.06.004. ［10］ OlivoMarston SE, Hursting SD, Perkins SN, et al. Effects of calorie restriction and dietinduced obesity on murine colon carcinogenesis, growth and inflammatory factors, and microRNA expression［J］. PLoS One, 2014, 9(4): e94765. DOI:10.1371/journal.pone.0094765. ［11］ Fouad MA, Agha AM, Merzabani MM, et al. Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: calorie restriction is the force to the cytotoxicity［J］. Hum Exp Toxicol, 2013, 32(10): 1067-1080. DOI:10.1177/0960327113475679. ［12］ Tsunoda T, Ota T, Fujimoto T, et al. Inhibition of phosphodiesterase4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3D coloniccrypt model［J］. Mol Cancer, 2012, 11: 46. DOI:10.1186/1476-4598-11-46. ［13］ Tsunoda T, Ishikura S, Doi K, et al. Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in threedimensional culture［J］. Anticancer Res, 2014, 34(8): 4551-4555. ［14］ Saud SM, Li W, Morris NL, et al. Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression［J］. Carcinogenesis, 2014, 35(12): 2778-2786. DOI:10.1093/carcin/bgu209. ［15］ Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates agingrelated metabolic phenotypes by inhibiting cAMP phosphodiesterases［J］. Cell, 2012, 148(3): 421-433. DOI:10.1016/j.cell.2012.01.017. ［16］ Aires V, Brassart B, Carlier A, et al. A role for peroxisome proliferatoractivated receptor gamma in resveratrolinduced colon cancer cell apoptosis［J］. Mol Nutr Food Res, 2014, 58(9): 17851794. DOI:10.1002/mnfr.201300962. ［17］ Galadari S, Rahman A, Pallichankandy S, et al. Tumor suppressive functions of ceramide: evidence and mechanisms［J］. Apoptosis, 2015, 20(5): 689711. DOI:10.1007/s10495-015-1109-1. ［18］ Ulrich S, Huwiler A, Loitsch S, et al. De novo ceramide biosynthesis is associated with resveratrolinduced inhibition of ornithine decarboxylase activity［J］. Biochem Pharmacol, 2007, 74(2): 281-289. DOI:10.1016/j.bcp.2007.04.001. ［19］ Shin KO, Park NY, Seo CH, et al. Inhibition of sphingolipid metabolism enhances resveratrol chemotherapy in human gastric cancer cells［J］. Biomol Ther (Seoul), 2012, 20(5): 470-476. DOI:10.4062/biomolther.2012.20.5.470. ［20］ Ji Q, Liu X, Han Z, et al. Resveratrol suppresses epithelialtomesenchymal transition in colorectal cancer through TGFβ1/Smads signaling pathway mediated Snail/Ecadherin expression［J］. BMC Cancer, 2015, 15: 97. DOI:10.1186/s12885-015-1119-y. ［21］ Ji Q, Liu X, Fu X, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via malat1 mediated Wnt/βcatenin signal pathway［J］. PLoS One, 2013, 8(11): e78700. DOI:10.1371/journal.pone.0078700. ［22］ Whitlock NC, Bahn JH, Lee SH, et al. Resveratrolinduced apoptosis is mediated by early growth response1, Krüppellike factor 4, and activating transcription factor 3［J］. Cancer Prev Res (Phila), 2011, 4(1): 116-127. DOI:10.1158/1940-6207.CAPR-10-0218. ［23］ Bottone FG Jr, AlstonMills B. The dietary compounds resveratrol and genistein induce activating transcription factor 3 while suppressing inhibitor of DNA binding/differentiation1［J］. J Med Food, 2011, 14(6): 584-593. DOI:10.1089/jmf.2010.0110. ［24］ Ali I, Braun DP. Resveratrol enhances mitomycin Cmediated suppression of human colorectal cancer cell proliferation by upregulation of p21WAF1/CIP1［J］. Anticancer Res, 2014, 34(10): 5439-5446. ［25］ Kaminski BM, Weigert A, Scherzberg MC, et al. Resveratrolinduced potentiation of the antitumor effects of oxaliplatin is accompanied by an altered cytokine profile of human monocytederived macrophages［J］. Apoptosis, 2014, 19(7): 1136-1147. DOI:10.1007/s10495-014-0988-x. ［26］ Osman AM, AlMalki HS, AlHarthi SE, et al. Modulatory role of resveratrol on cytotoxic activity of cisplatin, sensitization and modification of cisplatin resistance in colorectal cancer cells ［J］. Mol Med Rep, 2015, 12(1): 1368-1374. DOI:10.3892/mmr.2015.3513. ［27］ Nguyen AV, Martinez M, Stamos MJ, et al. Results of a phase Ⅰ pilot clinical trial examining the effect of plantderived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer［J］. Cancer Manag Res, 2009, 1: 25-37. ［28］ Patel KR, Brown VA, Jones DJ, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients［J］. Cancer Res, 2010, 70(19): 7392-7399. DOI:10.1158/0008-5472.CAN-10-2027. ［29］ Chow HH, Garland LL, Hsu CH, et al. Resveratrol modulates drug and carcinogenmetabolizing enzymes in a healthy volunteer study［J］. Cancer Prev Res (Phila), 2010, 3(9): 1168-1175. DOI:10.1158/1940-6207.CAPR-09-0155.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[10]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[11]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[12]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[13]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.
[14]	Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477.
[15]	Huang Mengpan, Wang Xuehong, Lu Yongfu. Mechanism of FOXA2 in colorectal cancer and its application in diagnosis and treatment [J]. Journal of International Oncology, 2022, 49(8): 490-493.